Mutations in some of these genes, such as PBRM1 and BAP1 in RCC, are associated with poor patient outcome (Joseph et al., 2016; Pawlowski et al., 2013), indicating that their downstream pathways may also contribute to cancer progression and metastasis. The gene discussed is PBRM1; the disease is renal cell carcinoma.